Pyrazoloacridine

Research use only, not for human use.

Pyrazoloacridine is a nucleic acid binding agent that inhibits the activity of topo I and II with an IC50 of 1.25 μM in K562 cells. Pyrazoloacridine shows anti-cancer activity.

Pyrazoloacridine is a nucleic acid binding agent that inhibits the activity of topo I and II with an IC50 of 1.25 μM in K562 cells. Pyrazoloacridine shows anti-cancer activity.(In Vitro):In oxic and hypoxic HCT-8 cells, Pyrazoloacridine exhibits IC50 values of 10.7 μM and 4.5 μM. Pyrazoloacridine causes delayed DNA fragmentation in MCF-7 cells and induces apoptosis in P53-deficient Hep 3B cells. Pyrazoloacridine exhibits activities against cisplatin- and paclitaxel-resistant ovarian cancer.

Pyrazoloacridine (NSC 366140, PD 115934) exhibits IC50 values of 10.7 μM and 4.5 μM for oxic and hypoxic HCT-8 cells.Pyrazoloacridine (NSC 366140, 2-4 μM) abolishes the catalytic activity of both topo I and topo II in vitro.Pyrazoloacridine (NSC 366140) displays activity against cisplatin- and paclitaxel-resistant ovarian cancer.Pyrazoloacridine (NSC 366140) has been shown to cause delayed DNA fragmentation in MCF-7 breast cancer cells.Pyrazoloacridine (NSC 366140) induces apoptosis in P53-deficient Hep 3B human hepatoma cells.Cell Cytotoxicity Assay Cell Line:K562 Myeloid Leukemia Cells.Concentration:0-500 μM.Incubation Time:1 h or 24 h.Result:When K562 cells were incubated with PA for 1 h and then plated in soft agar, an IC50 of -50 μM was observed. In contrast, when cells were incubated for 24 h with PA, the IC50 was 1.25 μM.

——

PD 115934 | PD-115934 | PD 115,934 | NSC 366140 | NSC-366140

Apoptosis

Apoptosis

Akt|PP2A|Apoptosis|CIP2A

——

——

99009-20-8

367.409

C19H21N5O3

>98% (HPLC)

In Vitro:?DMSO : 16.67 mg/mL (45.37 mM)

COc1ccc2[nH]c3c(ccc4n(CCCN(C)C)nc(c34)c2c1)[N+]([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years